Intravitreal Ranibizumab for neovascular Age-related macular degeneration in clinical practice: five-year treatment outcomes

被引:0
|
作者
Meidong Zhu
Jamie K. Chew
Geoffrey K. Broadhead
Kehui Luo
Nichole Joachim
Thomas Hong
Adil Syed
Andrew A. Chang
机构
[1] Sydney Institute of Vision Science,Save Sight Institute
[2] The University of Sydney,Statistics Department
[3] Macquarie University,undefined
关键词
Ranibizumab; Neovascular age-related macular degeneration (nAMD); As-needed treatment model; Five-year treatment; Exudative age-related macular degeneration; Wet macular degeneration;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:1217 / 1225
页数:8
相关论文
共 50 条
  • [1] Intravitreal Ranibizumab for neovascular Age-related macular degeneration in clinical practice: five-year treatment outcomes
    Zhu, Meidong
    Chew, Jamie K.
    Broadhead, Geoffrey K.
    Luo, Kehui
    Joachim, Nichole
    Hong, Thomas
    Syed, Adil
    Chang, Andrew A.
    GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2015, 253 (08) : 1217 - 1225
  • [2] Five-year treatment outcomes following intravitreal ranibizumab injections for neovascular age-related macular degeneration in Japanese patients
    Iori Wada
    Yuji Oshima
    Satomi Shiose
    Kumiko Kano
    Shintaro Nakao
    Yoshihiro Kaizu
    Shigeo Yoshida
    Tatsuro Ishibashi
    Koh-hei Sonoda
    Graefe's Archive for Clinical and Experimental Ophthalmology, 2019, 257 : 1411 - 1418
  • [3] Five-year treatment outcomes following intravitreal ranibizumab injections for neovascular age-related macular degeneration in Japanese patients
    Wada, Iori
    Oshima, Yuji
    Shiose, Satomi
    Kano, Kumiko
    Nakao, Shintaro
    Kaizu, Yoshihiro
    Yoshida, Shigeo
    Ishibashi, Tatsuro
    Sonoda, Koh-hei
    GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2019, 257 (07) : 1411 - 1418
  • [4] Pharmacogenetic Aspect of Intravitreal Ranibizumab Treatment in Neovascular Age-Related Macular Degeneration: A Five-Year Follow-Up
    Sengul, Elvan Alper
    Artunay, Ozgur
    Rasier, Rifat
    Kockar, Alev
    Afacan, Ceyda
    Hancer, Veysel Sabri
    Yuzbasioglu, Erdal
    OCULAR IMMUNOLOGY AND INFLAMMATION, 2018, 26 (06) : 971 - 977
  • [5] Long-term results of intravitreal ranibizumab treatment for neovascular age-related macular degeneration in clinical practice
    Arias, Luis
    EXPERT REVIEW OF OPHTHALMOLOGY, 2013, 8 (01) : 37 - 40
  • [6] Clinical outcomes after switching treatment from intravitreal ranibizumab to aflibercept in neovascular age-related macular degeneration
    Florian M. Heussen
    Qing Shao
    Yanling Ouyang
    Antonia M. Joussen
    Bert Müller
    Graefe's Archive for Clinical and Experimental Ophthalmology, 2014, 252 : 909 - 915
  • [7] Clinical outcomes after switching treatment from intravitreal ranibizumab to aflibercept in neovascular age-related macular degeneration
    Heussen, Florian M.
    Shao, Qing
    Ouyang, Yanling
    Joussen, Antonia M.
    Mueller, Bert
    GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2014, 252 (06) : 909 - 915
  • [8] Five-Year Reactivation After Ranibizumab or Aflibercept Treatment for Neovascular Age-Related Macular Degeneration and Polypoidal Choroidal Vasculopathy
    Kim, Jae Hui
    Kim, Jong Woo
    Kim, Chul Gu
    JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS, 2021, 37 (09) : 525 - 533
  • [9] METAANALYSIS OF REAL-WORLD OUTCOMES OF INTRAVITREAL RANIBIZUMAB FOR THE TREATMENT OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
    Kim, Leah N.
    Mehta, Hemal
    Barthelmes, Daniel
    Vuong Nguyen
    Gillies, Mark C.
    RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2016, 36 (08): : 1418 - 1431
  • [10] Six-year outcomes in neovascular age-related macular degeneration with ranibizumab
    Jacob, Julie
    Brie, Heidi
    Leys, Anita
    Levecq, Laurent
    Mergaerts, Filip
    Denhaerynck, Kris
    Vancayzeele, Stefaan
    Van Craeyveld, Eline
    Abraham, Ivo
    MacDonald, Karen
    INTERNATIONAL JOURNAL OF OPHTHALMOLOGY, 2017, 10 (01) : 81 - 90